Jordt Raymond M 4

What Happened

• Raymond M. Jordt, Chief Business Officer of Altimmune, had 14,600 restricted stock units (RSUs) vest on January 25, 2026. The RSUs converted to 14,600 shares (exercise/conversion code M) at $0 exercise price.
• To cover tax withholding related to the vesting, 3,855 of those shares were surrendered (code F) at $5.50 per share, yielding $21,203. Net shares delivered to Jordt = 14,600 − 3,855 = 10,745 shares.
• This was a vesting/tax-withholding event rather than an open-market sale or purchase; the conversion of RSUs is typically routine compensation.

Key Details

• Transaction date: January 25, 2026; Form 4 filed January 27, 2026 (appears timely).
• Vested/converted: 14,600 shares (derivative to common; code M); Shares surrendered for taxes: 3,855 @ $5.50 = $21,203 (code F).
• Net shares retained from the vesting: 10,745 shares.
• Footnotes: RSUs represent the right to one share upon vesting (F1). The surrendered shares were solely to cover taxes on vesting (F2). RSUs vest in substantially equal annual installments over four years beginning Jan 25, 2024 (F3).
• Amount of Altimmune common stock owned after the transaction is not disclosed in the filing.

Context

• This was a standard RSU vesting with shares withheld for tax purposes (a routine administrative transaction). It does not represent an open-market sale or a discretionary purchase by the insider.
• Because the vested RSUs had $0 exercise price, the economic effect is compensation income at vesting; the withholding of shares is a common way companies satisfy tax obligations.